

Inven2 — University of Oslo & Oslo University Hospital Technology Transfer Office

City Innovation Library · Good practice · Norway

Quality score: 62/100

Evidence strength: Moderate

Summary

Inven2, the University of Oslo/Oslo University Hospital's technology transfer office, helped launch 55 start-ups and sign 388 licence agreements between 2010 and 2020; its Algeta spin-out was sold to Bayer in 2013 for about NOK 17.6 billion (~USD 2.9 billion).

Key dimensions

Dimension	Score
Evidence of impact / measured results	3/3
Transferability / demonstrated replication	2/3
Scalability	1/3
Sustainability / continuity	3/3
Innovation	2/3
Inclusiveness / equity	0/3
Multi-stakeholder collaboration	2/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-07-20

[Inven2 AS \(University of Oslo / Oslo University Hospital\)](#) — accessed 2026-07-20

[Inven2 — About us](#) — accessed 2026-07-20

[Inven2 10-year track record \(2020 annual report\)](#) — accessed 2026-07-20

[CNBC: Bayer bids for Norway's Algeta \(deal reaches ~\\$2.9bn\)](#) — accessed 2026-07-20

Cite this — Evidoria. *Inven2 — University of Oslo & Oslo University Hospital Technology Transfer Office*. Persistent ID: 520907a4-3a32-4689-b246-10cf16cd9a8b.